Why the study?
It was unknown whether serum concentrations of IL-17, IL-18, Tregs, and Th17 cells differ between patients with chronic heart failure not associated with myocarditis and healthy individuals.
Are serum concentrations of IL-17, IL-18, Tregs, and Th17 cells altered in patients with chronic heart failure compared to healthy individuals?
Meta-Analysis
Are serum concentrations of IL-17, IL-18, Tregs, and Th17 cells altered in patients with chronic heart failure compared to healthy individuals?
Answers are grounded in this paper and cite their sources.
Serum levels of IL-17, IL-18, and Th17 are significantly elevated, while Tregs are decreased in chronic heart failure, suggesting utility as biomarkers for severity and potential therapeutic targets.
Background The objective of this study was to assess whether interleukin‐17 or 18 (IL‐17 or IL‐18), regulatory T cells (Tregs), and T helper17 (Th17) serum concentrations were different in chronic heart failure not associated with myocarditis compared to healthy individuals. Methods We searched MEDLINE and Embase for studies with data on IL‐17 or IL‐18 serum concentrations in patients with chronic heart failure. Forest plots were used to quantify results and depict the standard difference of means, 95% confidence interval (CI), and p value. Continuous outcomes were assessed as weighted mean differences (WMD) with their 95% CI. Results IL‐17 was significantly ( p < 0.05) higher in patients with heart failure. The combined effect size under the random effects model (MD = 40.00 pg/mL, 95% CI [6.04, 73.96], p < 0.001) showed a significant overall increase in IL‐17 serum levels in heart failure. Th17 was significantly ( p < 0.05) higher in patients with heart failure, and Tregs are significantly lower compared to persons without heart failure. The random effects model indicates an MD of 1.59 pg/mL (95% CI [0.88, 2.30]), highlighting significant elevation of TH17 levels in heart failure. For Tregs, the random effects model presented an MD of −2.96 pg/mL (95% CI [−4.52, −1.40]), both indicating a significant decrease in Treg levels in HF. Additionally, serum IL‐17 concentrations correlated with the severity of the reduction in LV ejection fraction. For IL‐18, all (five) studies reported a statistically significant increase in IL‐18 levels in HF. The pooled mean difference was 251.59 pg/mL (95% CI: 177.24–325.93 pg/mL) with a random effects model. Conclusion Serum IL‐17, IL‐18 Th17, and Treg count have utility for risk stratification for patients with heart failure, as biomarkers for heart failure severity and potential target pathways for treatment.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) conducted a meta-analysis in chronic heart failure not associated with myocarditis. IL-17, IL-18, Tregs, and Th17 serum concentrations vs. Healthy individuals was evaluated on IL-17 serum concentrations (MD 40.00 pg/mL, 95% CI 6.04-73.96, p=< 0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: